The indolinone term represents a family of compounds with valuable pharmacological activities, in different therapeutic areas, especially in antineoplastic activity, acting on abnormal cell proliferation, generally by causing protein kinase disorders [1] [2] [3] . Indolinones can act directly on tumor cells by selectively blocking tyrosine kinase receptors, proteins responsible for the proliferation and survival of tumor cells, or indirectly by blocking angiogenesis [1] [2] [3] [4] [5] . Moreover, these molecules can inhibit cyclin-dependent kinases, proteins involved in the processes of cell cycle control, transcription, cell differentiation, cell death and others [1] [2] [3] . Protein kinases play an important role in signal transduction, a strictly regulated cellular process. These proteins modulate cellular responses to external stimuli and influence a number of biological processes, such as cell migration, metabolism, proliferation, survival, differentiation and cycle 3 . Different indolinones have been studied in order to find alternatives to inhibit protein kinases associated with abnormal cell activities, most of them synthesized and some molecules already with patented technologies 1 . The action of indolinone derivatives has been described on MET, VEGF, FGF, FGF, PDGF, c-Kit receptors and others, thus with a potential multi-kinase inhibition effect, acting on several
. Despite the different approaches on cancer therapy and prevention, this disease remains one of the leading causes of death worldwide, making necessary the development of new drugs and therapies. The indolinones are pharmacologically important molecules, exhibiting promising and already proven effects in the treatment of cancer and other diseases. Thus, this study aimed on the characterization and chemical definition and identity of a new indolinone compound, produced in the secondary metabolism of Pseudomonas aeruginosa, as well as to evaluate the anticancer potential of this molecule.
Results
Isolation and Structure Elucidation. The compound 1 was obtained by purification of a metabolite broth used in the fermentation process of Pseudomonas aeruginosa LV wild-type strain, isolated from orange plant leaves. The structure and absolute configuration of (R)-(+)-2-heptyl-3-oxoindole-2-carboxylic acid was proposed for compound 1 ( Fig. 1 ) based on extensive spectroscopy including 2D NMR spectroscopy, electronic CD (ECD) calculation, and by high resolution mass spectrometry.
Compound 1 was assumed as an off-white amorphous powder, [α] D + 10.0 (C = 0.10, MeOH). The molecular formula was determined as C 16 H 21 NO 3 by the HR-ESI-MS ion peak at m/z 298.1450 [M + Na] + , in positive mode (Calculated for C 16 H 21 NO 3 Na, 298,1408). The NMR spectrum presented signals for indol-3-one moiety and nalkyl and carboxyl groups were confirmed by 1 H-and 13 C-NMR data assignments. In the 13 C-NMR spectra, the most significant information was the appearance of signals at δc 195.8 and 174.1 ppm, indicating the presence of the carbonyl function of the 3-oxindole moiety and carboxyl group, respectively. In addition, the quaternary carbon signals at δc 82.9, 119.1, and 140.4, as well as the signal of four sp 8 and carboxyl δ C 174.1 groups with the methylenic hydrogens in δ H 1.93 (H-11a) and 1.80 (H-11b) confirmed the assignment of these groups in C-1 and C-10 position, respectively. The confirmations that heptyl group is attached to the C-2 quaternary carbon was made by the correlation of the methylenic hydrogens in δ 1.93 (H-11a) and 1.80 (H-11b) with the signal at δ 82.9. The physical and spectral data of the products are given as supporting information ( Figures S1-S6) .
In order to determine the absolute configuration at C2 of 1, we used Density Functional Theory (DFT) to obtain geometry ground state and time dependent DFT to calculate its electronic excited states. DFT is the most used method to perform molecular quantum calculation, given its satisfactory results for geometry and electronic states and low computational cost. Its most notable characteristic is the electronic density as main variable, but it also yields exact ground state of a multi electronic systems, as ensured by the two theorems in which is based 12, 13 . For the analyzed systems, first we calculated the lowest energy conformation and then the electronic excited states were obtained. We chose functional B3LYP and basis set 6-31 G** as implemented on Gaussian 09 package.
For both compounds (R and S indolinone), we tested some conformational features: (i) hydrogen bonded to nitrogen and (ii) the torsion of carboxylic group. The final geometry has hydrogen pointing towards the oxygen on the carbonyl. Finally, with the structural lowest energy, excited states were calculated and a theoretical circular dichroism spectra (CD) was obtained following the equation shown on the reference 14 . The results showed that the ECD spectra of 1 shared the almost identical Cotton effect with the calculated CD for R, but opposite to the calculated CD of S indolinone structure, respectively (Fig. 2) . The structural absolute configurations of 1 was established with R.
Cytotoxic screening of Indolin-3-one (compound 1) on HepG2 cells and human erythrocytes.
To assess the cytotoxic effects of indolin-3-one, initially the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays were carried out using HepG2 cells treated with different concentrations of compound 1, at four distinct incubation times (Fig. 3) . At 24, 48 , and 72 h of incubation, indolin-3-one significantly decreased the proliferation of HepG2 cells from the concentration of 40 μM, and at 96 h from 30 μM. This effect intensified in a dose-and time-dependent manner. The polynomial regression analysis showed that for Additionally, a hemolytic assay was performed to evaluate the sensibility of human erythrocytes to indolin-3-one, using the same experimental conditions of MTT assays (Fig. 4) . This experiment was an additional test to confirm and select the concentrations of indolin-3-one that do not cause direct membrane damages and cellular death on healthy cells. Concentrations up to 60 μM of indolin-3-one did not cause physical damage to the erythrocyte membrane at any time of exposure, with significant hemolytic effect only observed at concentrations of 80 μM and above. It is worth mentioning that the percentage of hemolysis did not exceed 10% for all concentrations tested in 24 and 48 h, a parameter usually applied to indicate significantly cytotoxicity 15 .
Associated treatments of non-cytotoxic concentrations of indolin-3-one and chemotherapeutic doxorubicin on HepG2 cells. To evaluate the influence of non-cytotoxic concentrations of indolin-3-one on the therapeutic action of doxorubicin, 5 and 10 μM of indolin-3-one were associated with 4 different doses of doxorubicin and incubated for 24 and 48 h (Fig. 5) . The association of 5 μM induced a significant increase in the action of doxorubicin at 48 h of treatment. This increase was greater when the concentration of indolin-3-one raised to 10 μM, at both incubation times. At 48 h of treatment, the indolin-3-one at 10 μM allowed to halve As the hemolytic test results indicated that concentrations below 80 μM did not cause direct physical damage to erythrocytes membranes, the concentrations of 20, 40, and 60 μM were selected to assess the influence of indolin-3-one on the modulation of gene expression related to carcinogenesis. Furthermore, previously to mRNA extraction, the viability of HepG2 cells was verified using a Countess Automated Cell Counter (Thermo Fisher Scientific) and Trypan Blue reagent, using cells treated with 20, 40, and 60 μM of indolin-3-one, at 24 and 48 h. In all these conditions, the cell viability was greater than 90%. In general, indolin-3-one significantly modulated the expression of most genes in a dose and time-dependent manner (Figs 6 and 7, Tables S1 and S2). These results were similar to the viability of HepG2 cells evaluated by MTT assays. Within 24 h, the MET, c-MYC, CDK2, CDKN1A, CDKN2A, CCNA2, EG5, EIF, E2F1 and BIRC5 genes were up-regulated when cells were treated with 20 μM of indolin-3-one. In the same concentration, at 48 h of treatment, this pattern started to invert and almost all gene expression rates returned to normal, except for CCNA2 and EG5, which were down-regulated and E2F1 that was up-regulated. When concentration increased to 40 μM, at 24 h of treatment, only the CDK6, CCND1, E2F1 and TP53 genes were down-regulated. The other genes remained unchanged. At 48 h of treatment with 40 μM of indolin-3-one, the CDK2, CDK4, CCND1, CCNA2 and EG5 genes were down-regulated and only E2F1 gene was up-regulated. The treatment with 60 μM of indolin-3-one promoted the down-regulation of all genes, except for CDK4, CDKN2A, EG5 and EIF at 24 h of treatment, and CDK6, CDKN1A, CDKN2A, EIF and E2F1 at 48 h, which maintained a normal expression rate. It is noteworthy that although these genes have not presented significant changes like the others, they presented a tendency of decreasing expression.
Discussion
In addition to having a natural origin, the first differential evidence of the molecule described in the present study was the indolin-3-one scaffold, since the majority of indolinone compounds developed and marketed for cancer treatment is synthesized from indolin-2-one derivatives 1, 2, 11, 16 . In this context, the compound 1 also can be used as a novel precursor for chemical optimization. An initial assay was performed to evaluate the anticancer All expression levels, standard errors, 95% confidence index and p values are described in Table S1 . The process is NADH and NAD(P)H-dependent and it is also reduced in other cellular compartments, such as the cytoplasm and regions of the plasma membrane 17, 18 . So, the MTT assay allow us to make an assumption of the cell energetic state, which may or may not be from cell death or cycle arrest. A decrease in cellular proliferation of HepG2 cells treated with compound 1 was observed, starting at 40 µM, with dose-and time-dependent increasing effect. The hemolysis test, carried out in the same conditions of MTT assay, evidenced that concentrations up to 60 μM of indolin-3-one did not cause physical damage to the erythrocyte membrane at any time of exposure. The spectrophotometric detection of hemoglobin released by erythrocytes membrane injuries is an extremely sensitive technique, being especially important for agents that are also intended to be directly introduced into the bloodstream 19 . Due to its sensibility, this trial allowed an efficient selection of indolin-3-one concentrations that did not cause direct membrane damages, since there was no intention to work with concentrations capable of causing such cytotoxic effect or cell death. In addition, before the gene expression analysis, it was verified by Trypan Blue Exclusion assay that 20, 40 and 60 µM of indolin-3-one did not alter HepG2 cells viability at 24 and 48 h of treatment. These results suggested that the reduction of HepG2 cellular progression in concentrations up to 60 μM of indolin-3-one, was not due to direct physical injuries, or biological processes that induce membrane damages and death, but a consequence of some type of modulation at the genetic level. The gene expression analyses reinforced these findings, once all genes (except E2F1) were significantly down-regulated or presented a tendency of decreasing under indolin-3-one at 48 h, in a dose-and time-dependent manner. The MET gene has increased expression in a variety of cancers when compared to healthy tissues. Its binding to hepatocyte growth factor (HGF) triggers a cascade of reactions that results in a large number of biological responses, which contribute to tumorigenesis. For this reason, several approaches for blocking MET activation are under development, such as tyrosine kinase inhibitor molecules 8, 20, 21 . The data suggest that indolin-3-one treatment can keep MET suppressed and the cell would not become malignant by this activation pathway. There are previous approaches targeting MET in clinical practice and in preclinical phases of study, among them the use of antagonistic molecules, antibodies, inhibitors of protein kinases and those that reduce their expression 22, 23 , in which the newly described indolin-3-one would fit. As observed to MET, indolin-3-one can also suppress c-MYC gene expression. c-MYC depletion inhibits proliferation of human tumor cells at various stages of the cell cycle, being essential for sustaining proliferation [23] [24] [25] . Both c-MYC and MET are proto-oncogenes related to several cancer hallmarks, like sustaining proliferative signaling, evading growth suppressors, enabling replicative immortality and activating invasion and metastasis 25 . Thus, treatment with indolin-3-one has the potential to act on cancer hallmarks and contribute to a lower cell proliferation, contributing for the non-occurrence of other malignant pathways, interesting for the treatment of tumor cells. [23] [24] [25] [26] , were all down-regulated by indolin-3-one in a dose and time-dependent manner. Other correlated genes, although not significantly changed in 24 h treatment, also presented the same dose-and time-dependent reduction pattern. The evidence that CDKs, their regulators and substrates are targets for genetic alteration in different types of human cancer, has stimulated the search for chemical CDKs inhibitors [27] [28] [29] . Again, the compound described in the present study fulfills these goals, and more.
CCND1, CCNA2, CDK2, CDK4 and EG5, part of the main regulatory genes of cell cycle control and progression, also closely linked to cancer hallmarks and their related genes (as MET and c-MYC)
The search process for new anti-cancer agents is entering a new era: it has moved from identifying compounds that directly kill tumor cells towards a more mechanistic strategy, acting on molecular targets that underlie cell transformation [28] [29] [30] . Carcinogenesis is a complex event controlled by several signal transduction pathways. The broadly multivariate nature of the molecular-level changes involved in any cancer leads to specific hallmarks profiles, which makes the tumorigenesis a complex and multistep process that involves the accumulation of successive transformational events with multi-factorial etiology. Nevertheless, such events result in the acquisition of key hallmark characteristics that are shared by all cancer cells 11, 26 . In this context, a new generation of anticancer agents emerges in order to fulfill this purpose in a more specific and effective way, interfering in the signaling of oncogenic events, intrinsic and extrinsic to the tumor cells and to the tumor microenvironment, without the need of elaborated methodologies for their application 11, [27] [28] [29] . Among the main targets used for this objective, there are proto-oncogenes, tumor suppressors and tyrosine kinase receptors 11, [26] [27] [28] [29] . The indolin-3-one carries the characteristics of these new generation anticancer agents, as evidenced by the results of the present work, modulating favorably these target genes, even when non-cytotoxic concentrations are employed.
Beyond that, the association of indolin-3-one with half the therapeutic dose of doxorubicin promoted better action than twice the doxorubicin dose alone. Combined drugs are also less prone to elicit drug resistance, leading to some improved pharmacological properties than each individual compound. As indole nucleus is a central component of many natural and synthetic molecules with extensive biological activity, these compounds recently have been used as a "multi-target approach", in order to design and develop agents able to act simultaneously on multiple intracellular constituents and signaling pathways, leading to better therapeutic effects 11 . Once more, the indolin-3-one fits these purposes and, together with other molecules, it can be used in the development of hybrid drugs for multi-target cancer therapy, a new approach area to evade cancer drug resistance and to design new agents, built to specifically target intracellular components and signaling pathways in cancer 11 . In summary, a new indolin-3-one compound that contributes efficiently to this accomplishment was discovered. The identified compound has the necessary characteristics to reach objectives like the simultaneous modulation of more than one biological target for cancer chemotherapy; in combination chemotherapy, it can enable different mechanisms of action, thereby, being more effective, decreasing cancer cell resistance and minimally overlapping toxicity profile; thus reducing side effects and consequently improving patient compliance, among other characteristics. Taken together, these facts justify the continuity of future works for a more detailed characterization of the potentials evidenced in this first study.
SCiEnTiFiC RepoRtS | (2018) 8:12781 | DOI:10.1038/s41598-018-30893-w Methods General experimental procedures. Optical rotation and circular dichroism was measured on a JASCO P-2000 polarimeter and JASC0 J-815 CD spectrometer in MeOH, respectively. IR spectra were recorded on a Bomem MB-Series spectrometer, in a 100 to 3500 cm −1 spectral region, using KBr matrix HR-ESI-MS and spectrum was recorded in a ESI-MS Quattro LCZ (Micromass Manchester, UK). NMR spectra were recorded on a Varian Mercury Plus 300 MHz spectrometer (7.02 T), operated at 75 MHz for 13 C and 300 MHz for 1 H and 2D NMR and a Bruker (Avance III) 400 MHz instruments. Column chromatography was carried out in Silica gel (70-230 mesh, Merck) for vacuum liquid chromatography (VLC) and Silica gel C-18 (HF Bondesil C-18, Agilent) for flash chromatography (FC). Thin-layer chromatography (TLC) was performed on precoated silica gel aluminum sheets (Kieselgel 60 F254, 0.20 mm, Merck, Darmstadt, Germany) and visualized in UV 254 or 365 nm.
Bacterial strain. The bacteria used was Pseudomonas aeruginosa LV strain wild-type. This strain was isolated from leaves of orange plants, at Astorga city, Brazil. Glycerol stocks were prepared and stored at −20 °C. The LV strain was deposited in the Microbial Culture Collection of Laboratory of Microbial Ecology, Londrina State University, Brazil.
Process for metabolites production. The fermentation parameters such as medium, pH, inoculum load, agitation, aeration, temperature and culture age were standardized to optimize the growth of P. aeruginosa LV strain and the production of metabolites has been patented (Patent #PI0803350-1; www.inpi.gov.br) and described by de Oliveira et al. 31 . The culture was harvested and centrifuged at 9.000 rpm for 15 min at 4 °C. The metabolites were extracted five times from the cell-free culture supernatant using two volumes of dichloromethane each time and was named dichloromethane phase (DP). The extracts were pooled and concentrated by rotary evaporation at 40 °C.
Purification of metabolites.
The dichloromethane phase (DP) (60 mg/L) was purified by VLC, carried out Cell Line and Culture Conditions. The hepatocellular carcinoma cell line HepG2 is of great relevance to detect cytotoxic and genotoxic substances. This cell line is a tool for chemical risk assessment and is a well-established cellular model for in vitro anti-tumor efficiency assays [32] [33] [34] . For this reason, HepG2 cells were chosen to investigate the in vitro anti-tumor activity of indolin-3-one and its underlying mechanisms. In addition, the use of HepG2 cells is a good in vitro experimental model, for it expresses some inducible phase I and II metabolic enzymes and can predict in vitro hepatotoxic effects of drugs in humans 35, 36 . MTT Assay. Cytotoxicity was assessed using the MTT assay, based on the protocol described by Mosmann 37 , with modifications. Cell suspension was seeded at 1.0 × 10 4 cells per well in 96-well plates containing 200 μL of culture medium supplemented with 15% of FBS. After 24 h of stabilization, the medium of each well was removed and 9 different concentrations of the indolin-3-one (5, 10, 20, 30, 40, 60, 80 , 100, and 120 µM solubilized with 1% of methanol in DMEM plus 15% FBS) were added. A solvent control condition (DMEM + 15% FBS + 1% methanol) were also included and used as control to statistical analysis. After each treatment period (24, 48, 72 and 96 h), the culture medium was replaced by 100 µL of MTT (0.5 mg/ml), solubilized in serum-free DMEM and incubated for 4 h. Finally, the MTT solution was removed and the formazan crystals generated were solubilized using 100 µL of DMSO. The absorbance was measured using a Biotek spectrophotometer at 570 nm. The mean absorbance of each reaction was converted to cell viability (%) using the following equation: (mean absorbance treatment/mean absorbance control) × 100.
Hemolysis assay. The hemolytic activity of indolin-3-one was measured by the hemoglobin release assay according to protocol described by Alves et al. 38 , with modifications. Red Blood Cells (RBCs) from of a healthy individual with A + blood typing were used. Six hundred microliters (600 μL) of phosphate buffered saline (PBS) Gene expression analysis using RT-qPCR. Sixty thousand (6 × 10 4 ) cells per well were inoculated in a 24-wells plate with 1 mL of DMEM plus 15% FBS for 24 h at 37 °C and 5% CO 2 for stabilization. Then, the culture medium was replaced by the following treatments: 20, 40 and 60 μM of indolin-3-one in DMEM plus 15% FBS. We used 1% methanol in DMEM plus 15% FBS as control condition. The cultures were incubated for 24 and 48 h. Total RNA was extracted using Trizol Reagent, according to the supplier's instructions. The purity and concentration of isolated RNA were determined by spectrophotometer and RNA integrity and quality were verified by denaturing agarose gel electrophoresis 39 . Capillary electrophoresis using Bioanalyser 2100 (Agilent Technologies) was carried out to determine the RNA integrity number (RIN) (Figures S7 and S8 ). cDNA synthesis of each sample was done in triplicate in the Veriti Thermal Cycler (Applied Biosystems) using 250 ng of total RNA, diluted in a final volume of 16 µL, containing oligo dT (80 pmol), random primers (100 pmol) and dNTPs (0.5 mM). This first reaction mix was incubated for 10 min at 65 °C. Each reaction was then thermal shocked on ice and 4 µL of a second reaction mix was added 
Statistical analysis.
The absorbance values obtained from MTT and hemolysis assays were compared by ANOVA followed by Dunnet's test (p < 0.05) using the GraphPad Prism ® 5. In Indolin-3-one/DXR associated treatments we conducted ANOVA followed by Tukey's test (p < 0.05). The Software R was used for the polynomial regression analysis and the calculated IC 50 . Statistical validation of reference gene and gene expression levels were determined by the stand-alone software REST ® 2009 (Relative Expression Software Tool/Qiagen ® ) 42 . Statistical difference was defined as a 2-fold change variation plus a p value < 0.05, when each treatment was compared to the control, as well as fold change variations with p values of p ≤ 0.01.
